openPR Logo
Press release

Acute Ischemic Stroke Diagnosis and Treatment Market Growth Analysis 2020

11-14-2017 10:29 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Acute Ischemic Stroke Diagnosis and Treatment Market Growth

Transparency Market Research announces the release of a new research report titled “Acute Ischemic Stroke Diagnosis and Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”. According to the report, driven by technological advancement, growing prevalence of strokes, and high success rate of treatment surgeries, the global acute ischemic stroke diagnosis and treatment market is likely to expand at a 6.30% CAGR from 2014 to 2020, growing from US$1.2 bn to US$1.9 bn during that time.

Read Report Overview @ https://www.transparencymarketresearch.com/acute-ischemic-stroke-treatment.html

Based on type of diagnosis, the acute ischemic stroke diagnosis and treatment market is divided into CT, nuclear imaging, cerebral angiography, MRI, ultrasound, and others. While high efficiency and effectiveness of CTs enabled them to dominate the overall market, this segment is anticipated to witness limited demand by 2020 owing to technological complexities and high cost of diagnosis.

On the basis of type of surgery, the acute ischemic stroke diagnosis and treatment market is segmented into carotid endarterectomy, endovascular mechanical thrombectomy, and angioplasty. While carotid endarterectomy dominated the overall market thanks to short treatment duration, high success rate, and easy availability, this segment is anticipated to lose market share over the next five years owing to high risk of side effects.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1799

Geographically, the global acute ischemic stroke diagnosis and treatment market is divided into Asia Pacific, Europe, North America, and Rest of the World. Primarily driven by the rise in acute ischemic stroke surgeries and availability of technologically advanced medical equipment and devices, North America dominates the worldwide acute ischemic stroke diagnosis and treatment market. The American Heart Association states that every year, an estimated 795,000 patients are diagnosed with stroke in the US, a whopping 85.0% of which are identified as acute ischemic stroke. Seeing that the cost of treating strokes in the country surpasses US$73 bn per year, the North America acute ischemic stroke diagnosis and treatment market is anticipated to retain its lead through 2020.

Europe is the second largest market and is mainly fueled by a large population base of geriatrics. Identified as the most rapidly developing regional market for acute ischemic stroke diagnosis and treatment, Asia Pacific is driven by growing awareness among people, increasing number of global companies turning their focus to developing countries in APAC, expanding pool of potential patients, and rising investments in the region.

Request Acute Ischemic Stroke Diagnosis and Treatment Market Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1799

Some of the leading companies making a significant contribution towards the growth of the global acute ischemic stroke diagnosis and treatment market are Stryker Corporation, Abbott Laboratories, Hitachi, Ltd., Covidien plc, Siemens Healthcare, Penumbra, Inc., GE Healthcare, Philips Healthcare, and Johnson & Johnson.

Buy Full Acute Ischemic Stroke Diagnosis and Treatment Market Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1799<ype=S

About TMR

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Ischemic Stroke Diagnosis and Treatment Market Growth Analysis 2020 here

News-ID: 815296 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Acute

Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Acute Renal Failure (ARF) (Acute Kidney Injury) Market: Industry Size, Share, Gr …
Latest industry research report on: Acute Renal Failure (ARF) (Acute Kidney Injury) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape. Request For Sample Report
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H2
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230595 Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth